2022
Rasmussen M.B; Drljevid-Nielsen A; Thygesen J; Kruis M F; Hjorthaug K; Rasmussen F; Nijkamp J. Assesment of Correlation between Dual-Energy Ct (De-Ct)-Derived lodine Concentration and Local Flourodeoxyglucose (Fdg) Uptake in Patients with Primaty Non-Small-Cell Lung Cancer. MDPI, vol 8, https://www.mdpi.com/2379-139X/8/4/149
Review: Wen, S.W.C.; Wen, J.; Hansen, T.F.; Jakobsen, A.; Hilberg, O. Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer—A Systematic Review. Cancers 2022, 14, 2254. https://doi.org/10.3390/ cancers14092254
Juul A. D. · Falster C. · Rasmussen T.R. · Hilberg O. · Jacobsen N. · Arshad A. · Laursen C.B. Does the Addition of Radial Endobronchial Ultrasound Improve the Diagnostic Yield of Electromagnetic Navigation Bronchoscopy? A Systematic Review – Abstract – Respiration 2022, Vol. 101, No. 9 – Karger Publishers
Circulating tumor DNA monitoring reveals molecular progression before radiologic progression in a real-life cohort of advanced Non-Small Cell Lung Cancer patients. Frank M.S., Andersen C.S.A., Ahlborn L.B., Pallisgaard N., Bodtger U., Gehl J. Cancer Research Communications. Sept 2022. https://doi.org/10.1158/2767-9764.CRC-22-0258
Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment Frank, M.S., Bodtger, U., Gehl, J., Ahlborn, L.B. Cancers 2022, 14, 132. https://doi.org/10.3390/cancers14010132
2021
Skougaard K, Østrup O et.al: Surveillance with PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion ofDefinitive Therapy: A Randomized Controlles Trial (SUPER) Clinical Lung Cancer, 2020-0301 Volume 21, Issue 2: e61-e64.
Frank M, Bødtger U et. al: Re-biopsy after first line treatment in advances NSCLC can reveal changes in PD-L1 expression Lung Cancer, Volume 149: 23-32.
L. Winther, Kr. Larsen, WE. Langer, M. Quist: THE 6-MINUTE WALK TEST AS A PRE-TREATMENT PREDICTOR FOR ADVERSE EVENTS IN PATIENTS WITH LUNG CANCER: A FEASIBILITY STUDY
Malene Støchkel Frank, Uffe Bodtger, Julie Gehl and Lise Barlebo Ahlborn: Actionable Molecular Alterations are Revealed in Majority of Advanced NOn-Small Cell Lunge Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment
2020
Bødtger U, Høegholm A, Stamp IM, Gehl J Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression Frank MS, . Lung Cancer. Volume 149. 2020. P 23-32. https://doi.org/10.1016/j.lungcan.2020.08.020